

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CLARITY MEDICAL GROUP HOLDING LIMITED

清晰醫療集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1406)

APPOINTMENT OF FORENSIC ADVISOR TO SEPARATE SPECIAL COMMITTEE

The board (the “**Board**”) of directors (the “**Directors**”) of Clarity Medical Group Holding Limited (the “**Company**”) would like to refer to (i) the announcement of the Company dated 30 May 2025 in relation to the Resumption Guidance issued by the Stock Exchange, (ii) the announcement of the Company dated 30 June 2025 in relation to the additional Resumption Guidance given by the Stock Exchange; and (iii) the announcement of the Company dated 14 January 2026 providing quarterly updates on its business operations and resumption status. Unless otherwise stated, capitalised terms used in this announcement shall have the same meanings as those defined in the above-mentioned announcements.

APPOINTMENT OF FORENSIC ADVISOR TO THE SEPARATE SPECIAL COMMITTEE

Under the Resumption Guidance, the Company must conduct an independent forensic investigation into the Allegations and related matters, assess the impact on the Company’s business operations and financial position, announce the findings and take appropriate remedial actions.

The Separate Special Committee, having considered the background, experience and expertise of a number of candidates, recommended to the Board the appointment of Grant Thornton Advisory Services Limited (“**GT Advisory**”) as the forensic advisor to the Separate Special Committee, to conduct an independent forensic investigation on the Allegations on material misstatements in the Prospectus and to report its findings and conclusions to the Separate Special Committee and the Board. The appointment of GT Advisory was approved by the Board.

Further announcement(s) will be made by the Company to inform the Shareholders and the Stock Exchange of the key findings of GT Advisory as and when appropriate.

CONTINUED SUSPENSION OF TRADING

Trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on Tuesday, 15 April 2025 and will remain suspended until further notice.

Shareholders and potential investors of the Company should exercise caution when dealing in the shares or other securities of the Company, and if they are in any doubt about their position, they should consult their independent professional advisor(s).

CLARITY MEDICAL GROUP HOLDING LIMITED
JIANG Bo

Executive Director and Chief Executive Officer

Hong Kong, 5 March 2026

As at the date of this announcement, the Board comprises Mr. JIANG Bo as executive Director, Mr. CHEN Jiarong, Professor WANG Qinmei and Mr. SUN Peng as non-executive Directors, and Mr. WANG Can, Ms. CI Ying, Dr. CHEN Poujian and Mr. XU Anliang as independent non-executive Directors.